ArticleFrontiers in oncology2026
Hepatocellular carcinoma with renal invasion and its multimodal management: a rare case report.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This case report presents a 60-year-old female diagnosed with hepatocellular carcinoma (HCC) and direct renal invasion. Imaging identified a large hepatic mass involving the right kidney, which was confirmed histopathologically and supported by elevated alpha-fetoprotein (AFP) levels. Treatment involved a multimodal strategy combining transarterial chemoembolization (TACE), fractionated radiotherapy, and combination immunotherapy with camrelizumab plus apatinib. Follow-up imaging and AFP trends showed marked tumor regression and biochemical improvement. This case highlights the rare entity of direct renal invasion from HCC and provides practical insights into its diagnosis and comprehensive management. It illustrates the clinical feasibility and potential benefit of a combined locoregional and systemic strategy in advanced HCC with such uncommon extrahepatic renal involvement, underscoring the importance of individualized treatment in these complex presentations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.